News

CAESAREA, Israel, Nov. 04, 2019 (GLOBE NEWSWIRE) -- Itamar Medical Ltd., a company that develops, manufactures, and markets non-invasive diagnostic medical devices for sleep apnea and uses a digital healthcare platform to facilitate the...

Impulse Dynamics, developer of the implantable Optimizer Smart System for delivering CCM™ (Cardiac Contractility Modulation) therapy, announced that it has received FDA approval of a PMA supplement for its next generation, two-lead Optimizer...

Cardiva Medical, Inc., an innovator in the field of vascular closure, announced that positive results from the AMBULATE pivotal study demonstrating the safety and efficacy of the company’s VASCADE® MVP Venous Vascular Closure System compared...

CardioFocus, Inc., a medical device company dedicated to advancing ablation treatment for atrial fibrillation (AFib), announced that the first patients in France have been treated in the University Public Hospital of Nancy with the HeartLight...

Bardy Diagnostics, Inc. (BardyDx), a leading provider of ambulatory cardiac monitoring technologies and custom data solutions, announced that it was selected as winner of the "Remote Monitoring in Arrhythmias" Technology and Innovation Pitch...

Itamar Medical Ltd., a company that develops, manufactures and markets non-invasive diagnostic medical devices for sleep apnea and uses a digital healthcare platform to facilitate the continuum of care for effective sleep apnea management...

HOUSTON – (Oct. 21, 2019) – Atrial fibrillation is the most common heart arrhythmia in humans. This condition increases the risk of heart failure, stroke, dementia, and death, and current treatments have suboptimal efficacy and carry side...

The Bristol-Myers Squibb-Pfizer Alliance and Fitbit announced at the TIME 100 Health Summit in New York that they are working together to help drive timely diagnosis of atrial fibrillation (AFib) with the aim of improving earlier detection...

The Janssen Pharmaceutical Companies of Johnson & Johnson announced that the U.S. Food and Drug Administration (FDA) has approved XARELTO® (rivaroxaban) for the prevention of venous thromboembolism (VTE), or blood clots, in hospitalized...

Agreement includes partnership to produce the world-renowned Leipzig Interventional Course (LINC), and further establishes the company’s position as a leading global provider of healthcare events Malvern, PA (October 10, 2019) — HMP, a...